AbbVie to tap Vraylar messaging lessons, but also create a new position to promote key psychiatric drug from Cerevel buy

News
1

Cerevel’s emraclidine, which is in midstage testing and the jewel in AbbVie’s buyout crown, works differently. It’s a muscarinic M4 selective positive allosteric modulator, and it too will likely seek a schizophrenia license, as well as other labels.

1 Like
2

I had read in an article that KarXT accelerated the NDA for September of this year anticipating that its direct competition in a couple of years would be Emraclidine

1 Like
3

Interesting :thinking:. Thanks.

1 Like